


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A23L 1/222, A61K 31/35, A21D 13/00, C07D 311/30, C07H 17/07	A1	(11) International Publication Number: WO 00/15047 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/KR99/00548 (22) International Filing Date: 15 September 1999 (15.09.99) (30) Priority Data: 1998/37963 15 September 1998 (15.09.98) KR (71) Applicant: KOREA RESEARCH INSTITUTE OF BIO-SCIENCE AND BIOTECHNOLOGY [KR/KR]; #52, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). (72) Inventors: BOK, Song, Hae; Garam Apt., 15-1202, Samcheon-dong, Seo-gu, Daejeon 302-222 (KR). JEONG, Tae, Sook; Hanbit Apt. 127-1103, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). BAE, Ki, Hwan; #113-12, Goijeong-dong, Seo-gu, Daejeon 302-200 (KR). PARK, Yong, Bok; Garden Heights Apt., 102-203, Bumco-4-dong, Suseong-gu, Daegu 706-014 (KR). CHOI, Myung, Sook; Garden Heights Apt., 102-203, Bumco-4-dong, Suseong-gu, Daegu 706-014 (KR). MOON, Surk, Sik; Gomnaru Apt., 101-601, #5, Sinkwan-dong, Gongju-shi, Chungcheongnam-do 314-110 (KR). KWON, Yong, Kook; Hanbit Apt., 126-1307, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). LEE, Eun, Sook; #49-2, Daehung-3-dong, Jung-gu, Daejeon 301-013 (KR). HYUN, Byung, Hwa; Hanbit		Apt., 131-1401, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). CHOI, Yang, Kyu; Hanbit Apt., 137-706, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). LEE, Chul, Ho; Gyungseong Kunmaeul Apt., 120-1307, Galma-dong, Seo-gu, Daejeon 302-171 (KR). LEE, Sae, Bom; Hanbit Apt., 111-301, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). PARK, Young, Bae; Hyundai Apt., 83-206, Apgujeong-dong, Kangnam-gu, Seoul 135-110 (KR). KIM, Hyo, Soo; Hyundai Apt. 85-1401, Apgujeong-dong, Kangnam-gu, Seoul 135-110 (KR). (74) Agents: JANG, Seong, Ku et al.; KEC Building, 17th floor, #275-7, Yangjae-dong, Seocho-ku, Seoul 137-130 (KR). (81) Designated States: CA, CN, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOSITION CONTAINING NEOHESPERIDIN DIHYDROCHALCONE FOR PREVENTING OR TREATING EL-EVATED BLOOD LIPID AND GLUCOSE LEVEL-RELATED DISEASES (57) Abstract <p>A pharmaceutical composition for treating or preventing an el-evated blood lipid or glucose level-related disease such as hyperlipi-demia, arteriosclerosis, angina pectoris, stroke, hepatic diseases and hyperglycemia in a mammal, which comprises an effective amount of neohesperidin dihydrochalcone as an active ingredient together with a pharmaceutically acceptable carrier, and a functional food or beverage composition for such a disease, which comprises an effective amount of neohesperidin dihydrochalcone.</p> <div style="text-align: center; margin-top: 200px;">  </div>		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

COMPOSITION CONTAINING NEOHESPERIDIN DIHYDROCHALCONE FOR
PREVENTING OR TREATING ELEVATED BLOOD LIPID AND GLUCOSE
LEVEL-RELATED DISEASES

5 FIELD OF THE INVENTION

The present invention relates to a pharmaceutical composition for treating or preventing elevated blood lipid and glucose level-related diseases such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke, hepatic diseases and hyperglycemia in a mammal, which comprises an effective amount of neohesperidin dihydrochalcone as an active ingredient together with a pharmaceutically acceptable carrier; and a functional food or beverage composition for treating or preventing such diseases, which comprises an effective amount of neohesperidin dihydrochalcone.

BACKGROUND OF THE INVENTION

20 It has been reported that blood lipids, especially cholesterol and triglycerides, are closely related to various kind of diseases such as coronary cardio-circulatory diseases, e.g., arteriosclerosis and hypercholesterolemia, and fatty liver. Cholesterol, a fatty steroid alcohol, is a blood lipid produced from saturated fat in the liver. Triglycerides are another type of blood lipids which are known to increase the risk of various diseases. It has also been reported that an elevated blood or plasma cholesterol level causes the deposition of fat, macrophages and foam cells on the wall of blood vessels, such deposit leading to plaque formation and then to arteriosclerosis(see Ross, R., Nature, 362, 801-809(1993)). One of the methods for decreasing the plasma cholesterol level is alimentotherapy to reduce the ingestion of cholesterol and lipids. Another method is to inhibit the absorption of cholesterol by inhibiting enzymes involved therein.

Acyl CoA-cholesterol-o-acyltransferase(ACAT) promotes

- 2 -

the esterification of cholesterol in blood. Foam cells are formed by the action of ACAT and contain a large amount of cholesterol ester carried by low density lipoproteins. The formation of foam cells on the wall of artery increases with the ACAT activity, and, accordingly, an inhibitor of ACAT may also be an agent for preventing arteriosclerosis. - Further, it has been reported that the blood level of LDL-cholesterol can be reduced by inhibiting the ACAT activity(see Witiak, D. T. and D. R. Feller(eds.), Anti-Lipidemic Drugs: Medicinal, Chemical and Biochemical Aspects, Elsevier, pp159-195(1991)).

Further, it has been reported that hypercholesterolemia can be treated effectively by reducing the rate of cholesterol biosynthesis through the inhibition of cholesterol ester transfer protein(CETP) which mediates the cholesterol transfers between the lipoproteins, or 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase which mediates the synthesis of mevalonic acid, an intermediate in the biosynthesis of sterols or isoprenoids(see Cardiovascular Pharmacology, William W. Parmley and Kanu Chatterjee Ed., Wolfe Publishing, pages 8.6-8.7, 1994).

Therefore, numerous efforts have been made to develop medicines to inhibit HMG-CoA reductase; and, as a result, several compounds derived from Penicillium sp. and Aspergillus sp. have been commercialized. Specifically, Lovastatin® and Simvastatin® developed by Merck Co., U.S.A., and Pravastatin® developed by Sankyo Co., Japan, have been commercialized(see C.D.R. Dunn, Stroke: Trends, Treatment and Markets, SCRIPT Report, PJB Publications Ltd., 1995).

However, these medicines are very expensive and a long-term administration thereof is known to induce an adverse side effect to the central nervous system. Further, although Lovastatin® and Simvastatin® may reduce the plasma LDL cholesterol level by enhancing the activity of LDL receptor in the liver, they cause side effects such as increase in creatine kinase in the liver and rhabdomyolysis(see Farmer, J.A., et al., Bailliers-clin.

- 3 -

Endocrinol. Metal., 9, 825-847(1995)). Accordingly, there has continued to exist a need to develop an inexpensive and non-toxic inhibitor of HMG-CoA reductase.

Another example of the elevated blood-lipid level-related disease is fatty liver. In particular, the excessive intake of fat-containing foods and alcohol causes fatty liver wherein a large amount of lipids is deposited in the liver tissue and the levels of serum GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase) and γ -GTP(γ -glutamyl transpeptidase) are elevated(see T. Banciu et al., Med. Interne., 20, 69-71(1982); and A. Par et al., Acta. Med. Acad. Sci. Hung., 33, 309-319(1976)).

Fat accumulates in the liver mainly in the form of triglycerides and fatty acids, and also to a minor extent, in the form of cholesterol. Further, it has been reported that one of the major signs of fatty liver is high blood cholesterol and/or triglyceride contents. Therefore, fatty liver is closely related to the level of cholesterol and/or triglycerides in the blood.

On the other hand, hyperglycemia is a common disease that afflicts the adult population in developed countries. Hyperglycemia type I, e.g., insulin-dependent diabetes, can be treated by insulin administration, but more than 90% of hyperglycemia patients suffer from insulin-independent hyperglycemia for which insulin treatment is not effective. Although many drugs have been developed for insulin-independent hyperglycemia patients, they are still ineffective and relatively toxic.

Bioflavonoids are polyphenolic antioxidants which exist widely in the natural world, especially in vegetables, fruits, wine and the like. It has been reported that the bioflavonoids exhibit various useful pharmacological activities such as anti-inflammatory, capillary reinforcing, anti-oxidative, anti-cancer, anti-viral and anti-platelet aggregation activities(see O. Benavente-Garcia et al., Uses and properties of citrus flavonoids, J. Agr. Food Chem., 45,

4506-4515, 1997).

Representative bioflavonoids, which can be found in citruses, are listed in Table I.

Table I

5

Citrus fruit	Bioflavonoids
Grapefruit	apigenin, dihydrokaempferol, eriodictyol, hesperetin, hesperidin, isorhamnetin, isosakuranetin, kaempferol, naringenin, naringin, neohesperidin, poncirin, quercetin, rutin
Lemon	apigenin, apigenin 7-rutinoside, chrysoeriol, diosmin, eriocitrin, hesperidin, isorhamnetin, limocitrin, limocitrol, luteolin 7-rutinoside, naringin, neohesperidin, poncirin, quercetin
10 Orange	auranetin, hesperidin, isosakuranetin 7-rutinoside, naringin, neohesperidin, nobiletin, rutin, sinensetin, tangeretin, vitexin
Tangerine	hesperidin, nobiletin, tangeretin

Neohesperidin dihydrochalcone, a bioflavonoid which can be easily extracted from grapefruit or synthesized from naringin, is known to have a 1,000 to 1,500 fold higher sweetness than sucrose.

The present inventors have endeavored to develop a novel pharmacological use of bioflavonoids which are abundantly present in herbs, foodstuffs, vegetables and fruits. As a result, it has been discovered that neohesperidin dihydrochalcone is effective in treating or preventing elevated blood lipid and glucose level-related diseases. Specifically, it can greatly reduce plasma cholesterol level; prevent the activities of HMG-CoA reductase and ACAT; inhibit the accumulation of macrophage-lipid complex on the endothelial wall of an artery; prevent hepatic dysfunctions; and lower the blood glucose level in

- 5 -

a mammal.

SUMMARY OF THE INVENTION

5 Accordingly, it is an object of the present invention to provide a pharmaceutical composition containing-neohesperidin dihydrochalcone for treating or preventing an elevated blood lipid or glucose level-related disease.

10 Another object of the present invention is to provide a food or beverage composition containing neohesperidin dihydrochalcone for treating or preventing an elevated blood lipid or glucose level-related disease.

15 In accordance with one aspect of the present invention, there is provided a pharmaceutical composition for treating or preventing an elevated blood lipid or glucose level-related disease, which comprises neohesperidin dihydrochalcone as an active ingredient and pharmaceutically acceptable excipients, carriers or diluents.

20 BRIEF DESCRIPTION OF THE DRAWINGS

25 The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, in which:

 Figs. 1A, 1B and 1C show the arterial endothelium of the rabbits administered with 1% cholesterol; 1% cholesterol plus 1 mg/kg Lovastatin®; and 1% cholesterol plus 0.05% neohesperidin dihydrochalcone, respectively; and

30 Figs. 2A, 2B and 2C present the microscopic features of the livers of the rabbits administered with 1% cholesterol; 1% cholesterol plus 1 mg/kg Lovastatin®; and 1% cholesterol plus 0.05% neohesperidin dihydrochalcone, respectively.

35 DETAILED DESCRIPTION OF THE INVENTION

Throughout the specification, the term "blood lipid"

- 6 -

designates a lipid present in the blood, and "blood glucose", the glucose present in the blood. The blood lipid is represented by cholesterol and triglycerides carried in the blood.

5 The term "high or elevated level" of a blood lipid or glucose means higher than normal level, the normal level varying with specific conditions of a patient, such as age, gender and body weight. A high level of blood lipid or glucose is ordinarily considered to be harmful to health.

10 The term "elevated blood lipid level-related disease" or "elevated blood glucose level-related disease" means a disease which is caused by a high or elevated level of blood lipid or glucose, and/or a disease whose symptoms include a high or elevated level of blood lipid or glucose. Examples
15 of such a disease include hyperlipidemia, arteriosclerosis, angina pectoris, stroke, hepatic diseases such as fatty liver, hyperglycemia and the like.

Neohesperidin dihydrochalcone ($C_{28}H_{36}O_{15}$, M.W. 612.60, see Merck Index 11th ed. (1989)) can be easily extracted from the
20 peel of grapefruit, or synthesized from naringin in accordance with a conventional process.

Neohesperidin dihydrochalcone exerts inhibitory as well as therapeutic effects on elevated blood lipid and glucose level-related diseases, e.g., hyperlipidemia,
25 arteriosclerosis, angina pectoris, stroke, hepatic diseases and hyperglycemia. Further, in spite of its potent efficacy, neohesperidin dihydrochalcone exhibits no toxicity when it is orally administered to a mouse at a dose of 1,000 mg/kg. Moreover, it does not adversely affect on the liver
30 function.

A pharmaceutical formulation may be prepared in accordance with any of the conventional procedures. In preparing the formulation, the active ingredient is preferably admixed or diluted with a carrier, or enclosed
35 within a carrier which may be in the form of a capsule, sachet or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material

- 7 -

acting as a vehicle, excipient or medium for the active ingredient. Thus, the formulations may be in the form of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft and hard gelatin capsule, sterile injectable solution, sterile packaged powder and the like.

Examples of suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxy-benzoates, propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a mammal by employing any of the procedures well known in the art.

The pharmaceutical composition of the present invention can be administered via various routes including oral, transdermal, subcutaneous, intravenous and intramuscular introduction. In case of human, a typical daily dose of neohesperidin dihydrochalcone may range from about 0.1 to 500 mg/kg body weight, preferably 1 to 100 mg/kg body weight, and can be administered in a single dose or in divided doses.

However, it should be understood that the amount of the active ingredient actually administered ought to be determined in light of various relevant factors including the condition to be treated, the chosen route of administration, the age, sex and body weight of the individual patient, and the severity of the patient's symptom; and, therefore, the above dose should not be intended to limit the scope of the invention in any way.

Moreover, neohesperidin dihydrochalcone can be

- 8 -

advantageously incorporated in foods or beverages for the purpose of treating or preventing elevated blood lipid and glucose level-related diseases, e.g., hyperlipidemia, arteriosclerosis, angina pectoris, stroke, hepatic diseases and hyperglycemia. The foods or beverages may include meats; juices such as a vegetable juice(e.g., carrot juice - and tomato juice) and a fruit juice(e.g., orange juice, grape juice, pineapple juice, apple juice and banana juice); chocolates; snacks; confectionery; pizza; food products made from cereal flour such as breads, cakes, crackers, cookies, biscuits, noodles and the likes; gums; dairy products such as milk, cheese, yogurt and ice creams; soups; broths; pastes, ketchups and sauces; teas; alcoholic beverages; carbonated beverages; vitamin complexes; and various health foods.

The content of the neohesperidin dihydrochalcone in a food or beverage may range from 0.01 to 20 wt%, preferably, from 0.1 to 5 wt%.

As described above, neohesperidin dihydrochalcone can be used as an effective, non-toxic pharmaceutical agent for treating or preventing elevated blood lipid and glucose level-related diseases, e.g., hyperlipidemia, arteriosclerosis, angina pectoris, stroke, hepatic diseases and hyperglycemia.

The following Examples are intended to further illustrate the present invention without limiting its scope.

Further, percentages given below for solid in solid mixture, liquid in liquid, and solid in liquid are on a wt/wt, vol/vol and wt/vol basis, respectively, and all the reactions were carried out at room temperature, unless specifically indicated otherwise.

Example 1: Toxicity of Orally Administered Neohesperidin Dihydrochalcone

35

12 seven-week-old, specific pathogen-free ICR female mice, six female mice each weighing about 25 to 29 g and six

- 9 -

male mice each weighing about 34 to 38 g, were kept under an environment of $22\pm 1^{\circ}\text{C}$, $55\pm 5\%$ relative humidity and 12L/12D photoperiod. Fodder (Cheiljedang Co., mouse and rat fodder) and water were sterilized and fed to the mice.

5 Neohesperidin dihydrochalcone purchased from Aldrich-Sigma Chemical Co. (St. Louis, MO, U.S.A) was dissolved in 0.5 % Tween 80 to a concentration of 100 mg/ml, and the solution was orally administered to the mice in an amount of 0.2 ml per 20 g of mouse body weight. The solution was
10 administered once and the mice were observed for 10 days for signs of adverse effects or death according to the following schedule: 1, 4, 8, and 12 hours after the administration and, every 12 hours thereafter, the weight changes of the mice were recorded to examine the effect of neohesperidin
15 dihydrochalcone. Further, on the 10th day, the mice were sacrificed and the internal organs were visually examined.

All the mice were alive at day 10 and neohesperidin dihydrochalcone showed no toxicity at a dose of 1,000 mg/kg. The autopsy revealed that the mice did not develop any
20 pathological abnormality, and no weight loss was observed during the 10 day test period. Accordingly, it was concluded that neohesperidin dihydrochalcone is not toxic when orally administered to an animal.

25 Example 2: Effect of Neohesperidin Dihydrochalcone on Plasma Cholesterol, HDL-Cholesterol and Neutral Lipid Levels

(Step 1) Administration of neohesperidin dihydrochalcone to rats

30

20 three-week-old white Sprague-Dawley rats (Taihan laboratory animal center, Korea), each weighing about 90 to 110 g, were evenly divided into two dietary groups by a randomized block design. The rats of the two groups were
35 fed with two different high-cholesterol diets, i.e., AIN-76 laboratory animal diet (ICN Biochemicals, Cleveland, OH, U.S.A.) containing 1 % cholesterol (Control group) and 1 %

- 10 -

cholesterol plus 0.05 % neohesperidin dihydrochalcone (Neohesperidin dihydrochalcone group), respectively. The compositions of the diets fed to the two groups are shown in Table II.

Table II

Dietary group	Control	Neohesperidin dihydrochalcone
Component	(n=10)	(n=10)
Casein	20	20
D,L-methionine	0.3	0.3
Corn starch	15	15
Sucrose	49	48.95
Cellulose powder* ¹	5	5
Mineral mixture* ¹	3.5	3.5
Vitamin mixture* ¹	1	1
Choline citrate	0.2	0.2
Corn oil	5	5
Cholesterol	1	1
Neohesperidin dihydrochalcone* ²	-	0.05
Total	100	100

*¹ Purchased from TEKLAD premier Co. (Madison, WI, U.S.A.)

*² Purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.)

The rats were allowed to feed freely on the specified diet together with water for six weeks, the ingestion amount was recorded daily and the rats were weighed every 7 days, and then the record was analyzed. All rats showed a normal growth rate and there was observed no significant difference among the two groups in terms of the feed ingestion amount and the weight gain.

(Step 2) Determination of total cholesterol, HDL-cholesterol and neutral lipid content in blood

- 11 -

The effects of administering neohesperidin dihydrochalcone to rats on the plasma cholesterol and neutral lipid contents were determined as follows.

The rats of the two dietary groups obtained in Step 1 were sacrificed and blood samples were taken therefrom. The blood was allowed to stand for 2 hours and centrifuged at 3,000 rpm for 15 minutes and the supernatant was separated and stored in a deep freezer before use. The chemical analysis of blood was carried out by employing a blood chemical analyzer (CIBA Corning 550 Express, USA) to determine the changes in total cholesterol, HDL-cholesterol and triglyceride levels. The result is shown in Table III.

Table III

Lipid Conc.	Group	Control	Neohesperidin dihydrochalcone
Total-C (mg/dl)		135±28	115±10
HDL-C (mg/dl)		18±4	19±3
TG (mg/dl)		57±13	52±8
$\frac{\text{HDL-C}}{\text{Total-C}}$ (%)		13	16

- * Total-C: Total-cholesterol
- * HDL-C: HDL-cholesterol
- * TG: Triglyceride

As can be seen from Table III, the total plasma cholesterol level is reduced by 15 % in the Neohesperidin dihydrochalcone group, as compared with that of the Control group. Further, the neutral lipid content is reduced by 9 % in the Neohesperidin dihydrochalcone group, as compared with that of the Control group.

Example 3: Activity of Neohesperidin dihydrochalcone in ACAT Inhibition

(Step 1) Preparation of microsomes

- 12 -

To determine the effect of feeding neohesperidin dihydrochalcone to rats on the activity of ACAT, microsomes were separated from liver tissues to be used as an enzyme source.

5 1 g each of the livers taken from each group of rats of Example 2 was homogenized in 5 ml of homogenization medium (0.1 M KH_2PO_4 , pH 7.4, 0.1 mM EDTA and 10 mM β -mercaptoethanol). The homogenate was centrifuged at 3,000xg for 15 min. at 4°C and the supernatant thus obtained was
10 centrifuged at 15,000xg for 15 min. at 4°C to obtain a supernatant. The supernatant was put into an ultracentrifuge tube (Beckman) and centrifuged at 100,000xg for 1 hour at 4°C to obtain microsomal pellets, which were then suspended in 3 ml of the homogenization medium and
15 centrifuged at 100,000xg for 1 hour at 4°C. The pellets thus obtained were suspended in 1 ml of the homogenization medium. The protein concentration of the resulting suspension was determined by Lowry's method and then adjusted to 4 to 8 mg/ml. The resulting suspension was
20 stored in a deep freezer (Biofreezer, Forma Scientific Inc.).

(Step 2) ACAT assay

6.67 μl of 1 mg/ml cholesterol solution in acetone was
25 mixed with 6 μl of 10 % Triton WR-1339 (Sigma Co.) in acetone and, then, acetone was removed from the mixture by evaporation under a nitrogen flow. Distilled water was added to the resulting mixture to adjust the concentration of cholesterol to 30 mg/ml.

30 Added to 10 μl of the resulting aqueous cholesterol solution were 10 μl of 1 M KH_2PO_4 (pH 7.4), 5 μl of 0.6 mM bovine serum albumin (BSA), 10 μl of microsome solution obtained in (Step 1) and 55 μl of distilled water (total 90 μl). The mixture was pre-incubated in a water bath at 37°C
35 for 30 min.

10 μl of (1- ^{14}C) oleyl-CoA solution (0.05 μCi , final concentration: 10 μM) was added to the pre-incubated mixture

- 13 -

and the resulting mixture was incubated in a water bath at 37°C for 30 min. Added to the mixture were 500 µl of isopropanol:heptane mixture(4:1(v/v)), 300 µl of heptane and 200 µl of 0.1 M KH₂PO₄(pH 7.4); and the mixture was mixed vigorously using a vortex mixer and then allowed to stand at room temperature for 2 min.

200 µl of the resulting supernatant was put in a scintillation bottle and 4 ml of scintillation fluid(Lumac) was added thereto. The mixture was assayed for radioactivity with 1450 Microbeta liquid scintillation counter(Wallacoy, Finland). ACAT activity was calculated as picomoles of cholesteryl oleate synthesized per min. per mg protein(pmoles/min/mg protein). The result is shown in Table IV.

Table IV

Group	%Inhibition on ACAT activity
Control	0
Neohesperidin dihydrochalcone	20

As can be seen from Table IV, ACAT activity observed in the Neohesperidin dihydrochalcone group is lower than that of the Control group by 20 %.

Example 4: Activity of Neohesperidin dihydrochalcone in HMG-CoA Reductase Inhibition

In order to determine the activity of HMG-CoA reductase, Hulcher's method was employed after some modification(see J. Lipid Res., 14, 625-641(1973)). In this method, the concentration of the coenzyme-A(CoA-SH), which is produced when HMG-CoA is reduced to a mevalonate salt by the action of HMG-CoA reductase, is determined by spectroscopy and the activity of HMG-CoA reductase is

- 14 -

calculated therefrom.

(Step 1) Preparation of microsomes

5 3 g of liver tissue taken from each group of rats of
Example 2 was washed succesively with 100 ml of a cold-
saline(0.15M NaCl) and 100ml of a cold buffer solution
A(0.1M triethanolamine, HCl/0.2M EDTA/2mM
10 dithiothreitol(DTT)). The cold buffer solution A was added
to the liver tissue in an amount of 2 ml per 1 g of the
liver tissue and the mixture was homogenized with a
homogenizer. The homogenate was centrifuged at 15,000xg for
15 minutes, and then, the supernatant was ultracentrifuged
15 at 100,000xg for 60 minutes to obtain microsomal
precipitates. The precipitates thus obtained was washed
with a cold buffer solution A and kept in a 1.5ml tube at -
70°C.

(Step 2) HMG-CoA reductase activity assay

20

The reaction substrates used in HMG-CoA reductase
activity assay were as follows: i) buffer solution B: 0.1M
triethanolamine, HCl/0.02M EDTA(pH7.4), ii) HMG-CoA
solution: 150 μ moles/culture medium, and iii) NADPH solution
25 : 2 μ moles/culture medium.

The suspension(microsome) was mixed with the reaction
substrate and the mixture was placed in a centrifugation
tube and reacted at 37°C for 30 minutes. The reaction
mixture was treated with 20 μ l of 0.01M sodium arsenous and
30 allowed to stand for 1 minute, and then it was reacted with
100 μ l of citrate buffer solution(2M citrate/3% sodium
tungstate, pH 3.5) at 37°C for 10 minutes followed by
centrifugation at 25,000xg for 15 minutes to remove protein.
1ml of the supernatant thus obtained was transferred into a
35 tube with a cap and added thereto were 0.1ml of 2M tris-HCl
solution(pH 10.6) and 0.1ml of 2M tris-HCl solution(pH 8.0)
to adjust the pH of the reactant to 8.0.

- 15 -

Then, the reactant was mixed with 20 μ l of DTNB buffer solution (3mM DTNB/0.1M triethanolamine/0.2M EDTA, pH 7.4) and the absorbance of the mixture was determined at 412nm to calculate the amount of CoA-SH (activity of HMG-CoA reductase).

The extent of inhibition of HMG-CoA reductase activity by neohesperidin dihydrochalcone was calculated based on the above result. The result is shown in Table V.

Table V

10	Group	Inhibition of HMG-CoA reductase activity (%)
	Control	0
	Neohesperidin dihydrochalcone	30

15 As can be seen in Table V, the HMG-CoA reductase activity observed in the Neohesperidin dihydrochalcone group is lower than that of the Control group by 30 %.

Example 5: Effect of Administration of Neohesperidin
20 Dihydrochalcone to a Human on Plasma Lipid Metabolism

Two men in their mid-fifties were administered with a daily oral dose of 10mg/kg of neohesperidin dihydrochalcone in the form of a capsule for 60 days. The plasma
25 cholesterol and neutral lipid (triglyceride) contents were determined before and after the administration.

The plasma cholesterol and neutral lipid contents were reduced by the neohesperidin dihydrochalcone administration by 20 % and 15 %, respectively.

30

Example 6: Inhibition of Arteriosclerosis

(Step 1) Administration of neohesperidin dihydrochalcone to rabbits

35

30 three-month-old New Zealand White rabbits (Yeonam

- 16 -

Horticulture and Animal Husbandry College, Korea), each weighing about 2.5 to 2.6 kg, were raised under a condition of temperature $20 \pm 2^\circ\text{C}$, relative humidity $55 \pm 5\%$, and photoperiod 12L/12D. The rabbits were divided into 3 groups and 3 groups of rabbits were fed with 3 different diets, i.e., RC4 diet (Oriental Yeast Co., Japan) containing 1 % cholesterol (Control group); 1 % cholesterol plus 1 mg/kg Lovastatin® (Merck, U.S.A.) (Lovastatin group); and 1 % cholesterol plus 0.05 % neohesperidin dihydrochalcone (Neohesperidin dihydrochalcone group), respectively. RC4 diet comprises 7.6 % moisture, 22.8 % crude protein, 2.8 % crude fat, 8.8 % crude ash, 14.4 % crude cellulose and 43.6 % soluble nitrogen-free substances. Neohesperidin dihydrochalcone was purchased from Sigma Chemical Co. (St. Louis, MO).

The rabbits were fed for 6 weeks while being allowed free access to the diets and water.

(Step 2) Chemical Analysis of Blood

20

After six weeks, the rabbits were anesthetized with an intramuscular injection of ketamine (50 mg/kg) in the femoral region and sacrificed. A blood sample was taken from the heart of each rabbit, allowed to stand for 2 hours and centrifuged at 3,000 rpm for 15 minutes and the supernatant serum was separated and stored in a freezer before use.

The chemical analysis of blood was carried out by employing a blood chemical analyzer (CIBA Corning 550 Express, USA) to determine the changes in GOT, GPT, γ -GTP and total cholesterol levels. The results are shown in Table VI.

(Step 3) Analysis for fatty streak in the main artery

The chest of each of the rabbits sacrificed in Step 2 was incised. The downward portion of the main artery from the site 1 cm above the aortic valve was cut out in a length

- 17 -

of about 5 cm and the fat surrounding the main artery was removed. The main artery was incised in the middle along the longitudinal axis and pinned to a dish. The moist artery was photographed and, then, the staining of fatty streaks was carried out in accordance with the method of Esper, E., et al. (J. Lab. Clin. Med., 121, 103-110(1993)) as follows.

A part of the incised main artery was washed three times with anhydrous propylene glycol for 2 min and stained for 30 min. with a saturated solution of Oil Red O (ORO, Sigma Co.) dissolved in propylene glycol. Thereafter, the artery was washed twice with 85 % propylene glycol for 3 min. to remove remaining staining solution and, then washed with physiological saline. The artery was photographed and the photograph was traced. The area of stained region (fatty streak region) was determined with an image analyzer (LEICA, Q-600, Germany) and its proportion (%) to the total arterial area was calculated. The result is shown in Table VI.

Figs. 1A, 1B and 1C show the arteries of the rabbits administered with 1 % cholesterol (Control group); 1 % cholesterol plus 1 mg/kg Lovastatin® (Lovastatin group); and 1 % cholesterol plus 0.05 % neohesperidin dihydrochalcone (Neohesperidin dihydrochalcone group), respectively. As shown in Figs. 1A, 1B and 1C, a thick layer of macrophage-lipid complex was observed on the arterial endothelium of the rabbit administered with 1 % cholesterol, while no or very thin layers of macrophage-lipid complex were observed on the arterial endothelia of the rabbits administered with 1 % cholesterol plus 1 mg/kg Lovastatin® and 1 % cholesterol plus 0.05 % neohesperidin dihydrochalcone, respectively.

Accordingly, it is concluded that the neohesperidin dihydrochalcone composition of the present invention strongly inhibits the deposition of macrophages on the arterial endothelium.

(Step 4) Histologic observation of the organs

- 18 -

Portions of the main artery, heart, lung, liver, kidney and muscle were taken from each of the rabbits sacrificed in step 2 and visually examined to confirm that no pathogenic abnormality was found. One half of each portion of the organs was deep freezed and the other half was fixed in 10 % neutral buffered formalin for more than 24 hours. The fixed organ piece was washed sufficiently with tap water, dehydrated stepwise with 70 %, 80 %, 90 % and 100 % ethanol and, then, embedded in a paraffin by employing SHANDON[®], Histocentre 2, USA. The embedded organ piece was sectioned in 4 μ m thickness with a microtome (LSICA, RM2045, Germany) and stained with hematoxylin and eosin. The stained organ specimen was made transparent with xylene, mounted with permount, and then observed under a microscope to look for the presence of lesions. No lesion was observed in any of the organ specimen.

Example 7: Prevention of Hepatic Diseases

In order to evaluate the effects of feeding a high cholesterol diet with neohesperidin dihydrochalcone on liver tissues, the liver specimens taken from the sacrificed rabbit in Step 2 of Example 6 were treated in accordance with the procedure disclosed in Fogt F. and Nanji A., Toxicology and Applied Pharmacology, 136, 87-93, 1996; and Keegan A., et al., Journal of Hepatology 23: 591-600, 1995, and observed under a microscope to be classified into four grades, i.e., 1+(0-25%), 2+(26-50%), 3+(51-75), 4+(76-100%) based on the proportion of abnormal fat-containing cells around the central vein in the liver acinus. The result is shown in Table VI.

Figs. 2A, 2B and 2C present the microscopic features of the livers of the rabbits administered with 1% cholesterol; 1% cholesterol plus 1 mg/kg Lovastatin[®]; 1% and cholesterol plus 0.05% neohesperidin dihydrochalcone, respectively. In Figs. 2A and 2B, many cells containing excessive fat were observed around the central vein. In contrast, almost all

- 19 -

liver cells are of a normal shape in Fig. 2C, which suggested that neohesperidin dihydrochalcone can significantly inhibit the formation of fatty liver.

As can be seen from the above, the administration of neohesperidin dihydrochalcone can improve lipid metabolism in rabbit and liver function and inhibit the plaque-formation in the endothelium of the main artery and formation of fatty liver as shown in Table VI. The results were tested by student t-test by using Microsoft excel(version 7.0) program.

Table VI

Group	Total-C (mg/dl)	GOT (IU/l)	GPT (IU/l)	γ -GTP (IU/l)	A(%)	B
Control	1143 (± 260)	77 (± 8)	65 (± 9)	4.2 (± 1)	35 (± 14)	3.2 (± 0.3)
Lovastatin	1210 (± 263)	125 (± 19)	73 (± 9)	12.4 (± 0.8)	5 (± 4)	3.4 (± 0.5)
Neohesperidin dihydrochalcone	1293 (± 89)	53 (± 23)	42 (± 20)	7.8 (± 5)	12 (± 7)	2.7 (± 0.3)

- * Total-C: Total-cholesterol
 A: Proportion(%) of fatty streak region to the total arterial area
 B: Proportion of abnormal fat-containing cells

As can be seen from Table VI, administration of neohesperidin dihydrochalcone lowers serum GOT and GPT levels by 31 % and 35 %, respectively, as compared to the Control group. Especially, neohesperidin dihydrochalcone is more effective in reducing serum GOT and GPT levels than Lovastatin®.

Example 8: Effect of Neohesperidin Dihydrochalcone on the blood glucose level

20 three-week-old male Sprague-Dawley rats(Taihan

- 20 -

laboratory animal center, Korea) were raised on Lab. chow pellet fodder (Cheiljedang Co.) until the average weight of each rat reached 280g. Diabetes was induced in the rats by using streptozotocin, which has been known to act specifically on the β -cell of pancreas and to have no adverse effect on other organs, as follows (see Junod A, et al., J. Clin. Invest., 48, 2129-2139 (1969)).

Streptozotocin purchased from Sigma Chemical Co. was dissolved in a citrate buffer (pH 4.5) and the solution was intramuscularly injected to the rats at a dose of 45 mg/kg body weight. The concentration of the streptozotocin solution was controlled so that the maximum injection volume was under 1 ml. 24 hours after the injection, blood samples were taken from tail veins of the rats and the blood glucose level was measured by employing Glucocard II GT-1629 (Kyto Daiichi Kagaku Co., LTP, model 5616239). The blood glucose levels of the rats were within the range from 350 to 400 mg/dl, which demonstrated that diabetes was induced in all of the rats (normal value: 118 mg/dl).

The effect of administering neohesperidin dihydrochalcone to rats on the blood glucose level was determined as follows.

One day after the injection of streptozotocin, the rats were fasted for 6 hours and blood samples were taken from their tail veins to confirm the occurrence of hyperglycemia in the rats. Then, the rats were divided into two dietary groups (n=10) by a randomized block design.

The rats of the two groups were fed with AIN-76 (American Institute of Nutrition) semipurified diet (Control group); and AIN-76 semipurified diet containing 0.05% of neohesperidin dihydrochalcone (Neohesperidin dihydrochalcone group), respectively. The rats were kept for 5 weeks under a constant temperature ($25 \pm 2^\circ\text{C}$), humidity ($50 \pm 5^\circ\text{C}$) and natural illumination while being allowed free access to the diets and water.

At the end of the five week period, the rats were fasted for 12 hours and anesthetized with ether, and then,

- 21 -

blood samples were taken from the inferior vena cava. Each of the blood samples was centrifuged at 3,000 rpm at 4°C for 15 minutes to separate a serum. The blood glucose level of the serum was measured by employing Glucocard II GT-1629 (Kyto Daiichi Kagaku Co., LTP, model 5616239) and the result is shown in Table VII.

Table VII

Group	Glucose Level (mg/dl)	% Decrease
Control	730±65	-
Neohesperidin dihydrochalcone	550±40	25

As can be seen in Table VII, the blood glucose level in the Neohesperidin dihydrochalcone group is lower than that of the control group by 25 %.

Example 9: Effect of Administration of Neohesperidin Dihydrochalcone to a Human

Two men in their mid-fifties were administered with a daily oral dose of 8 mg/kg of neohesperidin dihydrochalcone for 2 months. The blood glucose level was determined before and after the administration.

The blood glucose level was reduced by the above treatment by 30 %.

Formulation 1: Preparation of Pharmaceutical Formulation

Hard gelatin capsules were prepared using the following ingredients:

	Quantity (mg/capsule)
Active ingredient (neohesperidin dihydrochalcone)	200
Vitamin C	50
<u>Lactose (carrier)</u>	<u>150</u>
Total	400mg

- 22 -

Formulation 2: Foods Containing Neohesperidin Dihydrochalcone

Foods containing neohesperidin dihydrochalcone were prepared as follows.

(1) Preparation of tomato ketchup and sauce

Neohesperidin dihydrochalcone was added to a tomato ketchup or sauce in an amount ranging from 0.01 to 10 wt% to obtain a health-improving tomato ketchup or sauce.

(2) Preparation of foods containing wheat flour

Neohesperidin dihydrochalcone was added to wheat flour in an amount ranging from 0.01 to 10 wt% and breads, cakes, cookies, crackers and noodles were prepared by using the mixture to obtain health-improving foods.

(3) Preparation of soups and gravies

Neohesperidin dihydrochalcone was added to soups and gravies in an amount ranging from 0.01 to 10 wt% to obtain health-improving soups and gravies.

(4) Preparation of ground beef

Neohesperidin dihydrochalcone was added to ground beef in an amount ranging from 0.01 to 10 wt% to obtain health-improving ground beef.

(5) Preparation of dairy products

Neohesperidin dihydrochalcone was added to milk in an amount ranging from 0.01 to 10 wt% to obtain health-improving milk, and various dairy products such as butter and ice cream were prepared therefrom.

In case of a cheese preparation, neohesperidin dihydrochalcone was added to coagulated milk protein; and, in case of a yogurt preparation, neohesperidin dihydrochalcone was added to coagulated milk protein obtained after the fermentation.

- 23 -

Formulation 3: Beverages Containing Neohesperidin
Dihydrochalcone

(1) Preparation of vegetable juice

5 100 to 5,000 mg of neohesperidin dihydrochalcone was
added to 1000 ml of a vegetable juice to obtain a health--
improving vegetable juice.

(2) Preparation of fruit juice

10 100 to 5,000 mg of neohesperidin dihydrochalcone was
added to 1000 ml of a fruit juice to obtain a health-
improving fruit juice.

Formulation 4: Health Foods Containing Neohesperidin
15 Dihydrochalcone

A health food was prepared by mixing the following
ingredients and tableting the mixture.

20		Quantity (wt/wt%)
	Ginseng powder or extract	50
	Neohesperidin dihydrochalcone	30
	<u>Sweetener and flavor</u>	<u>20</u>
	Total	100%

25

While the invention has been described with respect to
the above specific embodiments, it should be recognized that
various modifications and changes may be made to the
invention by those skilled in the art which also fall within
30 the scope of the invention as defined by the appended
claims.

- 24 -

What is claimed is:

1. A pharmaceutical composition for treating or preventing an elevated blood lipid or glucose level-related disease in a mammal, which comprises an effective amount of neohesperidin dihydrochalcone and pharmaceutically-acceptable excipients, carriers or diluents.

2. The composition of claim 1, wherein the disease is hyperlipidemia, arteriosclerosis, angina pectoris, stroke, fatty liver or hyperglycemia.

3. The composition of claim 1, wherein the mammal is human.

4. The composition of claim 1, wherein the effective amount of neohesperidin dihydrochalcone ranges from 0.1 to 500 mg/kg of body weight/day.

5. A food composition for treating or preventing an elevated blood lipid or glucose level-related disease in a mammal, which comprises neohesperidin dihydrochalcone in an amount ranging from 0.01 to 20 wt%.

6. The composition of claim 5, wherein the disease is hyperlipidemia, arteriosclerosis, angina pectoris, stroke, fatty liver or hyperglycemia.

7. The composition of claim 5, wherein the food is meat, chocolate, snack, confectionery, pizza, a health food product or a food product made from cereal flour, gums, dairy products, soups, broths, pastes, ketchups, sauces or vitamin complexes.

8. The composition of claim 7, wherein the food made from cereal flour is bread, cake, cracker, cookie, biscuit or noodle.

- 25 -

9. The composition of claim 7, wherein the dairy product is milk, ice cream, cheese or yogurt.


10. A beverage composition for treating or preventing
5 an elevated blood lipid or glucose level-related disease in a mammal, which comprises neohesperidin dihydrochalcone in an amount ranging from 0.01 to 20 wt%.

11. The composition of claim 10, wherein the disease
10 is hyperlipidemia, arteriosclerosis, angina pectoris, stroke, fatty liver or hyperglycemia.

12. The composition of claim 10, wherein the beverage
15 is a vegetable juice, fruit juice, tea, alcoholic beverage or carbonated beverage.


1/5

Fig. 1A




2/5

Fig. 1B



3/5

Fig. 1C



4/5

Fig. 2A






Fig. 2B



5/5

Fig. 2C



INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00548.

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁷: A 23 L 1/222; A 61 K 31/35; A 21 D 13/00; C 07 D 311/30; C 07 H 17/07

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: A 23 L; A 61 K; A 21 D; C 07 D; C 07 H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, PAJ, Internet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EC Sweeteners Directive (94/35/EC), 1994, page 1-4 [retrieved from the Internet: <URL: http://www.danisco-sugar.com/dssw/eng/about_suger/sweetlex/lagar.htm>	5-12
Y	JP 08-027006 A (TANABE SEIYAKU CO LTD), 03 June 1997 (03.06.97) Patent abstracts of Japan, Vol. 199605, 1996, 05.31 (abstract) Retrieved from EPOQUE.	1-4
Y	JP 09-143070 A (NIPPON FLOUR MILLS CO LTD), 03 June 1997 (03.06.97) Patent abstracts of Japan, Vol. 199710, 1997, 10.31 (abstract) Retrieved from EPOQUE.	1-4
A	US 3689663 A (MERCK AG E), 09 May 1972 (09.05.72), abstract; column 2, lines 10-19; claims.	1-12

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

02 December 1999 (02.12.99)

Date of mailing of the international search report

09 February 2000 (09.02.00)

Name and mailing address of the ISA/AT

Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/200

Authorized officer

Krenn

Telephone No. 1/53424/435

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/KR 99/00548


Patent document cited in search report			Publication date	Patent family member(s)			Publication date
JP	A2	8027006	30-01-1996	JP	B2	2814950	27-10-1998
JP	A2	9143070	03-06-1997			none	
US	A	3689663	05-09-1972	NL	A	6408925	01-03-1965
US	A	3689663	05-09-1972	BE	A	654204	01-03-1965
US	A	3689663	05-09-1972	CH	A	473114	31-05-1969
				CH	A	474503	30-06-1969
				CH	A	488687	15-04-1970
				DE	A	1493976	07-08-1969
				DE	B2	1493976	15-02-1973
				DE	C3	1493976	13-09-1973
				NL	B	142672	15-07-1974
				SE	B	332828	22-02-1971
				US	A	3450717	17-06-1969
				BE	A	652404	01-03-1965
				DE	A	1493967	20-02-1969
				DE	B2	1493967	08-02-1973
				DE	C3	1493967	06-09-1973
				BR	A0	6462132	02-08-1973
				DE	A	1493963	20-02-1969
				DE	B2	1493963	25-01-1973
				DE	C3	1493963	23-08-1973
				NL	A	6411867	12-04-1965

- 27 -

What is claimed is:


1. A pharmaceutical composition for treating or preventing an elevated blood lipid level-related disease in, a mammal, which comprises an effective amount of a cinnamic acid derivative of formula Ia or Ib, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients, carriers or diluents:

10



15

(Ia)



(Ib)

wherein,

R¹, R², R³, R⁴ and R⁵ are independently H, OH or C₁₋₄ alkoxy;

and

R⁶ is H, C₁₋₄ alkyl group, or C₅₋₇ cycloalkyl group having one or more substituents selected from the group consisting of OH, alkoxy and carboxy groups.

2. The composition of claim 1, wherein the disease is hyperlipidemia, arteriosclerosis, angina pectoris, stroke or fatty liver.

3. The composition of claim 1, wherein the mammal is human.

4. The composition of claim 1, wherein the effective amount of cinnamic acid derivative ranges from 0.1 to 500 mg/kg of body weight/day.


5. The composition of claim 1, wherein R¹, R², R³ and R⁵ are independently H or OH; R⁴ is H, OH or OCH₃; and R⁶ is

- 28 -

H or a cycloalkyl group substituted by one or more hydroxy groups and a carboxy group.

6. The composition of claim 1, wherein the cinnamic acid derivative is 4-hydroxycinnamic acid, 3,4-dihydroxycinnamic acid or 3,4-dihydroxyhydrocinnamic acid.

7. A food composition for treating or preventing an elevated blood lipid level-related disease in a mammal, which comprises a cinnamic acid derivative of formula Ia or Ib in an amount ranging from 0.01 to 20 wt%:



wherein, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in claim 1.

8. The composition of claim 7, wherein the disease is hyperlipidemia, arteriosclerosis, angina pectoris, stroke or fatty liver.

9. The composition of claim 7, wherein the cinnamic acid derivative is one of those wherein R¹, R², R³ and R⁵ are independently H or OH; R⁴ is H, OH or OCH₃; and R⁶ is H or a cycloalkyl group substituted by one or more hydroxy groups and a carboxy group.

10. The composition of claim 7, wherein the cinnamic acid derivative is 4-hydroxycinnamic acid, 3,4-dihydroxycinnamic acid, or 3,4-dihydroxyhydrocinnamic acid.

11. The composition of claim 7, wherein the food is

- 29 -

meat, chocolate, snack, confectionery, pizza, a health food product or a food product made from cereal flour, gums, dairy products, soups, broths, pastes, ketchups, sauces or vitamin complexes.


5

12. The composition of claim 11, wherein the food made from cereal flour is bread, cake, cracker, cookie, biscuit or noodle.

10


13. The composition of claim 11, wherein the dairy product is milk, ice cream, cheese or yogurt.

14. A beverage composition for treating or preventing an elevated blood lipid level-related disease in a mammal, which comprises a cinnamic acid derivative of formula Ia or Ib in an amount ranging from 0.01 to 20 wt%:



25

(Ia)



(Ib)

wherein, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in claim 1.

15. The composition of claim 14, wherein the disease is hyperlipidemia, arteriosclerosis, angina pectoris, stroke or fatty liver.

30

16. The composition of claim 14, wherein the cinnamic acid derivative is one of those wherein R¹, R², R³ and R⁵ are independently H or OH; R⁴ is H, OH or OCH₃; and R⁶ is H or a cycloalkyl group substituted by one or more hydroxy groups and a carboxy group.

35

- 30 -

17. The composition of claim 14, wherein the cinnamic acid derivative is 4-hydroxycinnamic acid, 3,4-dihydroxycinnamic acid, or 3,4-dihydroxyhydrocinnamic acid.

- 5 18. The composition of claim 14, wherein the beverage is a vegetable juice, fruit juice, tea, alcoholic beverage or carbonated beverage.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)